Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04106219 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
A Phase 1 study of Neuroblastoma, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
- 17
- Study locations
NCT04106219: Active Phase 1 study of Neuroblastoma, sponsored by Eli Lilly and Company.
NCT04106219 is a Phase 1 study of Neuroblastoma that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 71 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (70% lower). The trial reports 17 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04106219, a Phase 1 study of Neuroblastoma, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
- 17
- Study locations
Study Summary
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
Primary Outcome
Number of Participants with DLTs
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Topotecan
- DRUG LY3295668 Erbumine
Study Locations (17)
Other
- Institut Curie - Paris
- Universitätsklinikum Köln - Cologne
- Hospital Infantil Universitario Niño Jesús - Madrid
- Alder Hey Children's Hospital - Liverpool
California
- UCSF Medical Center at Mission Bay - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
Illinois
- University of Chicago - Comer Children's Hospital - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Ohio
- Cincinnati Childrens Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- Texas Childrens Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2020-06-11 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
What the registry record for NCT04106219 still lists
NCT04106219 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04106219 lists 17 locations in 14 states (Other, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT04106219 about?
NCT04106219 is a clinical study titled "A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma". The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
What is the current status of trial NCT04106219?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2020-06-11. Estimated completion is 2026-08.
What conditions does trial NCT04106219 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT04106219?
The interventions under investigation include: Cyclophosphamide (DRUG), Topotecan (DRUG), LY3295668 Erbumine (DRUG).
Who is sponsoring clinical trial NCT04106219?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04106219 being conducted?
This trial has 17 study locations across California, Colorado, Illinois, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04106219's enrollment target sits among peer trials
71 39th of 94 higher than 56 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI